Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Dtsch Dermatol Ges ; 2024 Aug 06.
Artículo en Inglés | MEDLINE | ID: mdl-39106217

RESUMEN

BACKGROUND: Trichophyton (T.) erinacei is a rare but emerging zoonotic dermatophyte that is rarely isolated as a human pathogen, with only a few cases extensively described in the literature. PATIENTS AND METHODS: We conducted a systematic search to identify eligible articles reporting demographics, clinical characteristics, and the therapeutic approach regarding T. erinacei infection in humans. RESULTS: 168 patients affected by T. erinacei were reported in the international literature between inception and November 2023. Only 56 cases (32.1%) were fully described. The median age at diagnosis was 26 years, the female/male ratio was around 2:1. The main source of the disease was the hedgehog. The infection presented with a combination of erythema, scaly plaques, pustules, papules, vesicles, oedema, and erosion; the most common locations were the hands and the head. The most frequently conducted examination was fungal culture, but gene sequencing and mass spectrometry improved both speed and precision in the most recent diagnostic course. Topical clotrimazole and systemic terbinafine were the most chosen treatment. CONCLUSIONS: Trichophyton erinacei should be considered in patients with erythematous scaly patches and recent contact with hedgehogs. Terbinafine should be considered as a first-line effective treatment, griseofulvin and azoles could be considered valid alternatives.

3.
BMC Microbiol ; 15(1): 260, 2015 Nov 09.
Artículo en Inglés | MEDLINE | ID: mdl-26552763

RESUMEN

BACKGROUND: The spread of carbapenem resistant Enterobacteriaceae (CRE) is an emerging clinical problem, of great relevance in Europe and worldwide. The aim of this study was the molecular epidemiology of CRE isolates in Valle d'Aosta region, Italy, and the mechanism of carbapenem resistance. RESULTS: Sixty consecutive CRE samples were isolated from 52 hospital inpatients and/or outpatients from November 2013 to August 2014. Genotyping of microbial isolates was done by pulsed-field gel electrophoresis (PFGE) and multi-locus sequence typing (MLST), carbapenemases were identified by PCR and sequencing. Carbapenem resistance gene transfer was performed by filter mating, plasmids from parental and transconjugant strains were assigned to incompatibility groups by PCR-based replicon typing. Molecular characterization of CRE isolates assigned 25 Klebsiella pneumoniae isolates to PFGE types A1-A5 and sequencing type (ST) 101, 17 K. pneumoniae isolates to PFGE type A and ST1789 (a single locus variant of ST101), 7 K. pneumoniae isolates to PFGE types B or C and ST512, 2 K. pneumoniae isolates to PFGE type D and ST405, and 5 Escherichia coli isolates to PFGE type a and ST131. All K. pneumoniae ST101 and ST1789 isolates were extended-spectrum beta-lactamase (ESBL) producers and carried bla CTX-M-1 group gene; 4 K. pneumoniae ST101 isolates were resistant to colistin. Molecular analysis of beta-lactamase genes identified bla KPC-2 and bla CTX-M-group 1 into conjugative plasmid/s assigned to IncFII incompatibility group in ST101 and ST1789 K. pneumoniae isolates, bla KPC-3 into conjugative plasmid/s assigned to IncF incompatibility group in ST512 and ST405 K. pneumoniae isolates, bla VIM-1 into conjugative plasmid/s assigned to IncN incompatibility group in ST131 E. coli isolates. CONCLUSIONS: The spread of CRE in Valle d'Aosta region was caused by the selection of KPC-2 producing K. pneumoniae ST101 and ST1789 epidemic clones belonging to clonal complex 101, KPC-3 producing K. pneumoniae epidemic clones assigned to ST512 and ST405, and VIM-1 producing E.coli ST131 epidemic clone. Carbapenem resistance, along with bla KPC-2, bla KPC-3 and bla VIM-1 carbapenemase genes, was transferred by conjugative plasmids assigned to IncFII, IncF, and IncN incompatibility groups, respectively, in filter mating experiments. The emergence of colistin resistance was observed in KPC-2 producing K. pneumoniae ST101 isolates.


Asunto(s)
Infecciones por Enterobacteriaceae/epidemiología , Infecciones por Enterobacteriaceae/microbiología , Enterobacteriaceae/fisiología , Klebsiella pneumoniae/fisiología , Epidemiología Molecular , Antiinfecciosos/farmacología , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Técnicas de Tipificación Bacteriana , Carbapenémicos/farmacología , Farmacorresistencia Bacteriana/genética , Enterobacteriaceae/efectos de los fármacos , Enterobacteriaceae/enzimología , Enterobacteriaceae/genética , Genotipo , Humanos , Italia , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/enzimología , Klebsiella pneumoniae/genética , Plásmidos/genética , beta-Lactamasas/genética , beta-Lactamasas/metabolismo
4.
Mediterr J Hematol Infect Dis ; 3(1): e2011041, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-22084655

RESUMEN

Artemisinin-combination therapies (ACTs) are recommended for the treatment of uncomplicated malaria in endemic areas with multidrug resistant Plasmodium falciparum. We report a case of possible artemether-lumefantrine clinical failure in an Italian traveler with uncomplicated P. falciparum malaria imported from Democratic Republic of Congo.

5.
J Nephrol ; 22(2): 295-8, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19384849

RESUMEN

This is the first case of documented treatment failure of JCV nephritis, despite a reduction of immunosuppressive agents and the use of antiviral therapy. We consistently detected high levels of JCV viremia, which correlated with the progressive deterioration of the graft and caused the final loss of the kidney, suggesting that JCV plays an etiological role in the onset of severe nephropathy in kidney transplant patients.


Asunto(s)
Rechazo de Injerto/etiología , Virus JC/genética , Fallo Renal Crónico/cirugía , Trasplante de Riñón , Infecciones por Polyomavirus/complicaciones , Infecciones Tumorales por Virus/complicaciones , Antivirales/uso terapéutico , Biopsia , ADN Viral/análisis , Diagnóstico Diferencial , Femenino , Estudios de Seguimiento , Rechazo de Injerto/patología , Rechazo de Injerto/terapia , Humanos , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Infecciones por Polyomavirus/terapia , Infecciones por Polyomavirus/virología , Diálisis Renal/métodos , Infecciones Tumorales por Virus/terapia , Infecciones Tumorales por Virus/virología
6.
J Clin Microbiol ; 43(10): 5272-4, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16207994

RESUMEN

Covert human immunodeficiency virus (HIV) replication was ongoing during the first 3 years of aviremia in 22 patients, as determined by detection of DNA containing two long terminal repeats (2 LTR DNA). Although total HIV DNA was detected in 60 2 LTR DNA-negative samples, the absence of 2 LTR DNA in 90% of patients following 7 to 8 years of highly active antiretroviral therapy suggests suppression of cryptic viral replication.


Asunto(s)
Terapia Antirretroviral Altamente Activa , ADN Viral/sangre , Duplicado del Terminal Largo de VIH/genética , VIH-1/genética , Viremia/tratamiento farmacológico , Integración Viral , ADN Viral/metabolismo , Infecciones por VIH/tratamiento farmacológico , VIH-1/fisiología , Humanos , Leucocitos Mononucleares/virología , Viremia/virología , Replicación Viral/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA